Cargando…
Investigation of the GnRH antagonist degarelix isomerization in biological matrices
One of the main objectives of peptide drug design is the improvement of peptide pharmacokinetics with maintaining biological activity, which can be achieved by the complex modifications of the primary structure of the peptides. However, these changes often lead to the formation of peculiar impuritie...
Autores principales: | Ferrazzano, Lucia, Tolomelli, Alessandra, Guryanov, Ivan, Macis, Marco, Abel, Ulrich, Ricci, Antonio, Cabri, Walter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10350552/ https://www.ncbi.nlm.nih.gov/pubmed/37455491 http://dx.doi.org/10.1002/prp2.1117 |
Ejemplares similares
-
Treatment with a GnRH receptor agonist, but not the GnRH receptor antagonist degarelix, induces atherosclerotic plaque instability in ApoE(−/−) mice
por: Knutsson, Anki, et al.
Publicado: (2016) -
In Search of the Molecular Mechanisms Mediating the Inhibitory Effect of the GnRH Antagonist Degarelix on Human Prostate Cell Growth
por: Sakai, Monica, et al.
Publicado: (2015) -
Comparison of GnRH Agonist, GnRH Antagonist, and GnRH Antagonist Mild Protocol of Controlled Ovarian Hyperstimulation in Good Prognosis Patients
por: Stimpfel, Martin, et al.
Publicado: (2015) -
Inhibitory effects of long-term repeated treatments of a sustainable GnRH antagonist, degarelix acetate, on caprine testicular
functions
por: KAWATE, Noritoshi, et al.
Publicado: (2020) -
GnRH agonist versus GnRH antagonist in assisted reproduction cycles: oocyte morphology
por: Cota, Ana Marcia M, et al.
Publicado: (2012)